Upcoming Webinar
Optimizing DLBCL Patient Outcomes with clonoSEQ MRD Monitoring
Date: September 29, 2025 | 2:00 PM
For patients with DLBCL, minimal residual disease (MRD) testing can mean more than just numbers on a report — it can help guide therapy choices, inform surveillance, and give patients clarity about what comes next.
In this session, Tara Graff, DO, MS (Mission Cancer + Blood) and Jay Patel, PharmD, BCOP (Adaptive Biotechnologies) will share how MRD monitoring fits into real-world care: when to use it, how to interpret results, and how to talk about them with patients in a way that builds trust and understanding.
What You’ll Learn:
- A clear view of why MRD monitoring matters in DLBCL
- Practical examples of how to use clonoSEQ to track therapy response and long-term outcomes
- Communication strategies that help patients feel supported, not overwhelmed, by their results
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.